Tiziana Life Sciences plc: Tiziana Announces Submission of a Patent Application for Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients
Go back to Tiziana Life Sciences plc: Tiziana Announces Submission of a Patent Application for Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients| (NASDAQ: TLSA) | Delayed: 1.16 +0.08 (7.41%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.08 | 52 Week High | $ | |||
| Open | $1.10 | 52 Week Low | $ | |||
| Day High | $1.16 | P/E | N/A | |||
| Day Low | $1.06 | EPS | $ | |||
| Volume | 290,851 | |||||
